Longevity News

Engineering Probiotic Consortia to Improve Chemotherapy Tolerance and Reduce Toxicity in Breast Cancer Patients: A New Frontier in Supportive Precision Oncology

Source: Frontiers - Health • Published: 14 Aug 2026, 00:00

Engineering Probiotic Consortia to Improve Chemotherapy Tolerance and Reduce Toxicity in Breast Cancer Patients: A New Frontier in Supportive Precision Oncology

Survey of engineered multi-strain probiotic consortia as supportive interventions to reduce chemotherapy toxicity and preserve gut health in breast cancer care.

Key Takeaways
  • You have multiple emails registered with Frontiers: You don't have a Frontiers account ?
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY)
  • Distribution or reproduction in other forums is permitted
Read Original Source

Continue exploring

Related longevity signals

Frontiers - HealthThe transformative impact of ultra-rapid nanopore sequencing in precision medicineAn overview of how ultra-rapid nanopore sequencing is accelerating clinical genomics and enabling real-time applications across diagnostics and personalized care.Swiss BiotechNewBiologix and Synastra partner on gene therapy manufacturingA biotech partnership story about developing stable producer cell lines for scalable gene therapy manufacturing; a forward-looking take on enabling DMD program development.PR NewswireAnbogen Therapeutics and The University of Tokyo Enter Collaborative Research Agreement to Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication ExpansionComparative oncology collaboration examining a selective cancer therapy in naturally occurring animal tumors to guide which human indications and combinations to pursue.Frontiers - HealthPredictive modeling of axillary web syndrome in Chinese postoperative breast cancer patients using interpretable machine learningA paper develops and validates interpretable machine learning models to predict axillary web syndrome risk after breast cancer surgery, comparing algorithms and clinical predictors.